Therapeutic targeting of CD8+ Tregs, such as increasing functional CD8+ Treg numbers or restoring NOX2 production in CD8+ Tregs, may control not only GCA but also age-related inflammation or “inflammaging” (58, 60–62). Here, CD8A is linked to temporal arteritis.